Merck and Neuromed Pharmaceuticals have discontinued development of NMED-160 (also known as MK-6721), a Phase II compound for the treatment of chronic pain. Their joint research collaboration will continue to evaluate other therapeutic candidates. While no serious adverse events with the drug were observed in clinical trials, it was determined that MK-6721 does not demonstrate the “ideal pharmaceutical characteristics considered necessary to advance the compound further in development...